Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2021 · 10-Q
Revenue$8.13K$8.13K— vs Q3 2020 Net Income-$3.29M-$3.29MN/M vs Q3 2020 EPS Diluted-$0.03-$0.03N/M vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
-$3,278,456
N/M
Operating Cash Flowderived-$532,840N/M Margins · derivedGross margin100.0%
Operating margin-40340.3%
Net margin-40503.0%
ended Sep 30, 2021 · filed Nov 22, 2021 · 53 d after period end